857
Participants
Start Date
May 2, 2017
Primary Completion Date
February 14, 2025
Study Completion Date
February 28, 2027
LOXO-292
Oral LOXO-292
Royal North Shore Hospital, St Leonards
Rigshospitalet, Copenhagen
Peter MacCallum Cancer Centre, Melbourne
Kantonsspital Luzern, Lucerne
Hospital Universitari Vall d'Hebron, Barcelona
National Taiwan University Hospital, Taipei
NYU Langone, New York
Memorial Sloan Kettering Cancer Center, New York
National Cancer Center, Goyang-si
APHM Hôpital de la Timone, Marseille
Seoul National University Bundang Hospital, Seongnam
Roswell Park Cancer Institute, Buffalo
University of Pennsylvania Hospital, Philadelphia
Thomas Jefferson University, Philadelphia
Istituto Nazionale dei Tumori, Milan
University of Maryland Medical Center, Baltimore
Johns Hopkins University, Baltimore
USO-Virginia Cancer Specialists, PC, Fairfax
University of North Carolina, Chapel Hill
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Madrid Norte Sanchinarro, Madrid
Mayo Clinic in Florida, Jacksonville
Memorial Hospital Pembroke, Pembroke
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux
Institut du Cancer de Montpellier - Val d'aurelle, Montpellier
Sarah Cannon Research Institute SCRI, Nashville
Taichung Veterans General Hospital, Taichung
Cleveland Clinic Foundation, Cleveland
University of Michigan, Ann Arbor
START Midwest, Grand Rapids
Universitätsklinikum Köln, Cologne
University of Wisconsin-Madison Hospital and Health Clinic, Madison
University of Chicago Medicine-Comprehensive Cancer Center, Chicago
Washington University Medical School, St Louis
Centre Leon Berard, Lyon
Ochsner Clinic Foundation, New Orleans
Hôpital Européen Georges Pompidou, Paris
University of Texas MD Anderson Cancer Center, Houston
Sarah Cannon Research Institute at HealthOne, Denver
Huntsman Cancer Institute, Salt Lake City
Mayo Clinic of Scottsdale, Scottsdale
Comprehensive Cancer Centers of Nevada, Las Vegas
UCLA Medical Center, Los Angeles
University of California - San Diego, San Diego
Hoag Memorial Hospital Presbyterian, Newport Beach
Irvine Medical Center, Orange
UCSF Medical Center at Mission Bay, San Francisco
Kaiser Permanente Medical Center, Walnut Creek
Gustave Roussy, Villejuif
Universitätsklinikum Würzburg A. ö. R., Würzburg
Oregon Health and Science University, Portland
National Cancer Centre Singapore, Singapore
Prince of Wales Hospital, Hong Kong
Sheba Medical Center, Ramat Gan
Soroka Medical Center - Pediatric Outpatient Clinic, Beersheba
Shaare Zedek Medical Center, Jerusalem
Hadassah Medical Center, Jerusalem
City of Hope National Medical Center, Duarte
Kaiser Permanente, Oakland
Yale Cancer Center, New Haven
Emory University, Atlanta
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Mayo Clinic, Rochester
Ohio State University Hospital, Columbus
Vanderbilt University Medical Center, Nashville
University of Texas Southwestern Medical Center at Dallas, Dallas
BC Cancer Vancouver, Vancouver
Nagoya University Hospital, Nagoya
National Cancer Center Hospital East, Kashiwa
Hokkaido University Hospital, Sapporo
Hyogo Cancer Center, Akashi
Kanazawa University Hospital, Kanazawa
Kindai University Hospital, Osaka Sayama-shi
Tominaga Hospital, Nagaizumi-cho,Sunto-gun
National Cancer Center Hospital, Chuo-ku
Japanese Foundation for Cancer Research, Koto
Tottori University Hospital, Yonago
National Hospital Organization Kyushu Cancer Center, Fukuoka
Okayama University Hospital, Okayama
Osaka City General Hospital, Osaka
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Royal Marsden Hospital, London
Collaborators (1)
Loxo Oncology, Inc.
INDUSTRY
Eli Lilly and Company
INDUSTRY